Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-75dct Total loading time: 0 Render date: 2024-05-16T02:06:32.448Z Has data issue: false hasContentIssue false

Stimulants

from Part II - Medication Reference Tables

Published online by Cambridge University Press:  19 October 2021

Edited by
Michael Cummings  and
Stephen Stahl
Michael Cummings
Affiliation:
University of California, Los Angeles
Stephen Stahl
Affiliation:
University of California, San Diego
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Management of Complex Treatment-resistant Psychotic Disorders , pp. 404 - 433
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Garnock-Jones, K. P., Keating, G. M. (2009). Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs, 11, 203–226.CrossRefGoogle ScholarPubMed
Stahl, S. M., Grady, M. M., Munter, N. (2017). Prescriber’s Guide: Stahl’s Essential Psychopharmacology. Cambridge: Cambridge University Press.Google Scholar
Laboratories., Prasco (2020). Atomoxetine Package Insert. Mason, Ohio.Google Scholar
Michelson, D., Adler, L., Spencer, T., et al. (2003). Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry, 53, 112–120.CrossRefGoogle ScholarPubMed
Kelsey, D. K., Sumner, C. R., Casat, C. D., et al. (2004). Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics, 114, e1–e8.CrossRefGoogle ScholarPubMed
Stiefel, G., Besag, F. M. (2010). Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf, 33, 821–842.CrossRefGoogle ScholarPubMed

References

Fry, J. M. (1998). Treatment modalities for narcolepsy. Neurology, 50, S43–48.CrossRefGoogle ScholarPubMed
Stahl, S. M., Grady, M. M., Munter, N. (2017). Prescriber’s Guide: Stahl’s Essential Psychopharmacology. Cambridge: Cambridge University Press.Google Scholar
SpecGx LLC. (2020). Dextroamphetamine Package Insert. Webster Groves, Missouri.Google Scholar
Vinson, D. C. (1994). Therapy for attention-deficit hyperactivity disorder. Arch Fam Med, 3, 445–451.Google Scholar
Jadad, A. R., Boyle, M., Cunningham, C., et al. (1999). Treatment of attention-deficit/hyperactivity disorder. Evid Rep Technol Assess (Summ), i–viii, 1–341.Google Scholar
Wender, P. H., Wolf, L. E., Wasserstein, J. (2001). Adults with ADHD. An overview. Ann N Y Acad Sci, 931, 1–16.CrossRefGoogle ScholarPubMed
Greenhill, L. L., Pliszka, S., Dulcan, M. K., et al. (2002). Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry, 41, 26S–49S.CrossRefGoogle ScholarPubMed
Stiefel, G., Besag, F. M. (2010). Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf, 33, 821–842.CrossRefGoogle ScholarPubMed

References

Shire US Inc. (2019). Lisdexamfetamine Package Insert. Lexington, Massachusetts.Google Scholar
Biederman, J., Krishnan, S., Zhang, Y., et al. (2007). Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther, 29, 450–463.CrossRefGoogle ScholarPubMed
Stahl, S. M. (2020). Stahl’s Essential Psychopharmacology Prescriber’s Guide. 7th ed. New York: Cambridge University Press.CrossRefGoogle Scholar

References

Stahl, S. M., Grady, M. M., Munter, N. (2017). Prescriber’s Guide: Stahl’s Essential Psychopharmacology. Cambridge: Cambridge University Press.Google Scholar
Sandoz Inc. (2019). Methylphenidate Package Insert. Princeton, New Jersey.Google Scholar
Keating, G. M., Figgitt, D. P. (2002). Dexmethylphenidate. Drugs, 62, 1899–1904; discussion 1905–1908.CrossRefGoogle ScholarPubMed

References

Fry, J. M. (1998). Treatment modalities for narcolepsy. Neurology, 50, S43–48.CrossRefGoogle ScholarPubMed
Stahl, S. M., Grady, M. M., Munter, N. (2017). Prescriber’s Guide: Stahl’s Essential Psychopharmacology. Cambridge: Cambridge University Press.Google Scholar
Teva Pharmaceuticals USA Inc. (2020). Dextroamphetamine saccharate, amphetamine as partate, dextroamphetamine sulfate and amphetamine sulfate tablets (mixed salts of a single entity amphetamine product) Package Insert. Parsippany, New Jersey.Google Scholar
Greenhill, L. L., Pliszka, S., Dulcan, M. K., et al. (2002). Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry, 41, 26S–49S.CrossRefGoogle ScholarPubMed
Stiefel, G., Besag, F. M. (2010). Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf, 33, 821–842.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Stimulants
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Stimulants
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Stimulants
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×